Physician profile
Eric John Smith
NPI 1093195430
$2,341.01
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $642 · 2021: $469 · 2022: $80.53 · 2023: $212 · 2024: $135 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.93 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.31 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $343.41 | 2019-2023 | Tezspire |
| Glaxosmithkline, LLC. | $297.18 | 2019-2025 | Trelegy Ellipta, Nucala |
| Abiomed | $143.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $134.42 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $112.12 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $106.43 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $78.92 | 2019-2021 | |
| Intuitive Surgical, INC. | $76.30 | 2025 | |
| Boston Scientific Corporation | $66.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $53.79 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.15 | 2021-2024 | Glassia |
| Merck Sharp & Dohme LLC | $34.26 | 2019-2020 | |
| Amarin Pharma, INC. | $33.34 | 2020-2021 | |
| Insmed, INC. | $31.69 | 2025 | Arikayce |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $29.04 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Jazz Pharmaceuticals INC. | $20.51 | 2021 | |
| Eisai INC. | $19.42 | 2021 | |
| Gilead Sciences, INC. | $18.99 | 2021 | |
| Amgen INC. | $17.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.22 | 2022 | |
| Phadia US INC. | $16.55 | 2019 | |
| La Jolla Pharmaceutical Company | $15.23 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.79 | 2019 | |
| Genentech USA, INC. | $14.27 | 2020 | |
| Shire North American Group INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.